TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 21.3% in October

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 62,100 shares, an increase of 21.3% from the September 30th total of 51,200 shares. Based on an average daily trading volume, of 47,100 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.4% of the company’s stock are short sold.

TriSalus Life Sciences Price Performance

Shares of TLSI opened at $4.00 on Wednesday. The business’s fifty day moving average price is $4.63 and its 200 day moving average price is $6.26. TriSalus Life Sciences has a 12-month low of $3.32 and a 12-month high of $10.42. The stock has a market capitalization of $117.24 million, a PE ratio of -1.60 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $7.36 million during the quarter. As a group, research analysts anticipate that TriSalus Life Sciences will post -1.53 earnings per share for the current fiscal year.

Insider Activity

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of TriSalus Life Sciences stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of hedge funds have recently added to or reduced their stakes in TLSI. Wolverine Asset Management LLC bought a new stake in TriSalus Life Sciences in the second quarter valued at $240,000. Highbridge Capital Management LLC bought a new stake in TriSalus Life Sciences in the second quarter valued at $1,184,000. Finally, Duquesne Family Office LLC lifted its stake in TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TLSI. Northland Securities began coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Finally, Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $12.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.